Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic-Guided Therapy for Major Depressive Disorder
NCT07738497Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2026
- Primary completion
- Jan 2029
01
Overview
Randomised, single-blind trial of antidepressant (TDDS/ODF) in major depressive disorder (MDD) (2 arms), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 12-Week Response Rate Defined by HAMD-17 Score Reduction. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
antidepressant (TDDS/ODF)
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07738497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738497.